<?xml version="1.0" encoding="UTF-8"?>
<p>Finally, in trial No. 23, 50 participants (from 18 years and older, treated with standard therapy) of both sexes have been enrolled in order to study quercetinâ€™s efficacy both as prophylaxis in COVID-19-negative participants and as treatment in COVID-19-positive patients.</p>
